Disease/Infection News

RSS
SARS-CoV-2 N501Y mutation adversely affects cellular immune response

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Study: Only 14% of the Bernese population developed antibodies against SARS-CoV-2

Study: Only 14% of the Bernese population developed antibodies against SARS-CoV-2

Study shows psychological impact of perceived COVID-19 health threat among Black Americans

Study shows psychological impact of perceived COVID-19 health threat among Black Americans

COVID-19 vaccination alone may not end the pandemic

COVID-19 vaccination alone may not end the pandemic

Dialysis patients are 4 times more likely to die from COVID-19

Dialysis patients are 4 times more likely to die from COVID-19

ZyCoV-D SARS-CoV-2 DNA vaccine shows robust immunogenicity and protective efficacy in Rhesus macaquesys

ZyCoV-D SARS-CoV-2 DNA vaccine shows robust immunogenicity and protective efficacy in Rhesus macaquesys

Researchers call for trials of rapamycin to treat COVID-19

Researchers call for trials of rapamycin to treat COVID-19

Phase I/II trial findings support use of CoronaVac vaccine in older individuals

Phase I/II trial findings support use of CoronaVac vaccine in older individuals

New study supports UK’s delay of the SARS-CoV-2 Pfizer vaccine second dose

New study supports UK’s delay of the SARS-CoV-2 Pfizer vaccine second dose

virusPHIX™ virus inactivation medium launched by RNAssist & Rapid Labs Ltd.

virusPHIX™ virus inactivation medium launched by RNAssist & Rapid Labs Ltd.

Researchers develop thermostable RNA vaccine delivery platform

Researchers develop thermostable RNA vaccine delivery platform

What are public preferences for COVID-19 vaccine prioritization strategies across the globe?

What are public preferences for COVID-19 vaccine prioritization strategies across the globe?

South African SARS-CoV-2 variant neutralized by two Chinese vaccines in case study

South African SARS-CoV-2 variant neutralized by two Chinese vaccines in case study

Pfizer vaccine and Eli Lilly monoclonal antibodies successfully neutralize SARS-CoV-2 UK variant, finds study

Pfizer vaccine and Eli Lilly monoclonal antibodies successfully neutralize SARS-CoV-2 UK variant, finds study

Monoclonal antibodies against SARS-CoV-2 spike's N-terminal prove highly protective in vivo

Monoclonal antibodies against SARS-CoV-2 spike's N-terminal prove highly protective in vivo

Researchers develop prototype COVID-19 vaccine using DNA vaccine platform

Researchers develop prototype COVID-19 vaccine using DNA vaccine platform

Politicians must justify for mishandling COVID-19 pandemic, argues senior editor

Politicians must justify for mishandling COVID-19 pandemic, argues senior editor

Study shows how SARS-CoV-2 evades immune responses

Study shows how SARS-CoV-2 evades immune responses

Poll data shows disparities in older adults’ ability to isolate COVID-19 persons in homes

Poll data shows disparities in older adults’ ability to isolate COVID-19 persons in homes

SARS-CoV-2 has developed worrying new mutation in UK

SARS-CoV-2 has developed worrying new mutation in UK

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.